Azithromycin for child survival in Niger
Part of Infections clinical trials.
This study tests if giving azithromycin to women and young children in rural Niger can reduce deaths and track antibiotic resistance. It aims to improve child survival in communities where access to healthcare is limited.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must live in a rural area in a participating region of Niger.
- For women: you must be between 12 and 55 years old and be selected for monitoring.
- For children: your child must be between 1 month and 5 years old and be selected for monitoring.
- You or your caregiver must give verbal permission to join.
- You cannot take part if you have a known allergy to antibiotics like azithromycin (a macrolide).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether adding a special device (the Guardian Spatial Emanator) to the AZVINIR II azithromycin program helps prevent malaria. It involves checking households and health centers in high-malaria areas in Africa.
This study tests whether adding the antibiotic azithromycin to standard nutritional care helps young children with severe acute malnutrition recover better. It is for children aged 6 to 59 months in Burkina Faso who have uncomplicated malnutrition and are not currently on antibiotics.
This trial tests whether giving azithromycin to newborns who are smaller at birth can improve health outcomes in the first weeks of life. Your baby may be eligible if they meet specific age, feeding, and safety requirements.
This trial tests whether the antibiotic azithromycin can help children in the hospital who are having asthma-like breathing symptoms. If you qualify, your child may get azithromycin as part of the study and will be monitored closely for side effects and breathing improvement.
This trial tests whether azithromycin (an antibiotic) can improve outcomes for babies and young children in the ICU who have RSV causing serious breathing problems. It mainly looks at children who start strong breathing support soon after RSV symptoms begin.
This study tests whether giving nutrition supplements (SQ-LNS) to healthy young children increases vaccination rates and prevents malnutrition in rural communities in Chad and Niger. Researchers will also track children's health outcomes and interview families about their experiences.
Hear when a new Mortality trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.